IAS Newsletter 2026 - Oral and Injectable PrEP for Men Who Travel for Work in South Africa and Uganda - Mobile Men Six-Monthly Newsletter

Sep 27, 2026

Uploaded by lilac

IAS Newsletter 2026 summarizes Mobile Men’s six-monthly initial results on delivering oral and injectable PrEP to HIV-negative men who travel for work in South Africa and Uganda. The project compared daily and event-based oral regimens with long-acting injectable CAB-LA, reporting trial design, primary and secondary endpoints, and randomized-phase outcomes. Findings highlight feasible same-day HIV testing and CAB-LA initiation, higher persistence with CAB-LA, and community-focused dissemination of results alongside upcoming cost-effectiveness and qualitative work.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages2

Reading Time5 min

AccessFree to download

Trial design and endpoints

Randomisation phase

Choice phase

Primary and secondary endpoints

Key results from the randomized phase

Testing and CAB-LA initiation feasibility

Persistence and preferences

Oral PrEP dosing preferences

Study implications and dissemination

Why choice matters

Community results dissemination

Results yet to come

Cost-effectiveness and modelling

Interviews and focus groups

Contact information

IAS Newsletter 2026 Oral and Injectable PrEP for men who travel for work in South Africa and Uganda Welcome to the MOBILE MEN six-monthly newsletter – we have initial RESULTS! For the past 3 years, we have been exploring how to deliver oral and injectable PrEP to men who travel for work. In East London and KwaZulu-Natal in South Africa, this mainly comprises taxi and truck drivers, whilst in Masaka, Uganda, this is focused on fishermen and people working in the fishing industry. For oral PrEP, men could choose to use daily or event-based (2+1+1) regimens. How was the trial designed? Phase 1: Randomisation: 400 HIV negative men were randomised to oral or injectable PrEP for 9 months. Phase 2: Choice Phase: men choose what type of PrEP they wanted to use for 9 months. What were study endpoints? Primary: Persistence on PrEP and PrEP choices Secondary: Attitudes and preferences towards PrEP options, cost-effectiveness, HIV self-test, STI, HIV. Key results from the randomised phase of study Presented by Dr Eugene Ruzagira at IAS conference 29th July: • Same-day HIV testing and CAB-LA initiation has highly acceptable and feasible for mobile men in Uganda and South Africa. • CAB-LA users had approx. 2.5× higher odds of persisting on PrEP compared with oral PrEP users • At month 9, 58% of men chose CAB-LA vs 42% oral PrEP (p=0 .01); the proportion choosing CAB-LA was lower than reported in other high-risk populations • Among oral PrEP users, event-based PrEP (alone or combined with daily) was preferred to dailyonly dosing overall. • Event-driven dosing predominated in South Africa compared to Uganda Dr Eugene Ruzagira presenting at IAS conference, Rio, Brazil. Also, please see our poster entitled“PrEP Beyond Prevention: Negotiating social lives, responsibility and risk: Insights from South Africa & Uganda”TUPED297 Our thoughts The study demonstrates that having choice matters. Long-acting injectable CAB-LA achieved higher persistence and was preferred overall; however, many men continued to prefer oral PrEP, particularly event-driven dosing. This suggests that expanding access to a range of PrEP options will be essential to reaching diverse populations and ensuring that HIV prevention services are responsive to men’spreferences and circumstances. Results dissemination with communities A key milestone for Mobile Men was the dissemination of study findings to participating communities in South Africa and Uganda. The results were shared with communities almost at the same time as they were presented at AIDS 2026, ensuring equitable and timely access to study outcomes. These dissemination events provided an opportunity to acknowledge participants' contributions, discuss the findings, and reinforce the study's commitment to community-centred research. Results yet to come - Cost-effectiveness and modelling of oral v injectable PrEP - Interviews and focus group discussions with participants and local communities Contact information Julie Fox, MOBILE MEN Project Director, [julie.fox@kcl.ac.uk](julie.fox@kcl.ac.uk)[ ](julie.fox@kcl.ac.uk)Website: MOBILE MEN-King's College London ([kcl.ac.uk](kcl.ac.uk))

FAQs

Who is the Mobile Men PrEP study targeting in South Africa and Uganda?

The study focuses on HIV-negative men who travel for work. In South Africa, it mainly includes taxi and truck drivers, while in Uganda it includes fishermen and people working in the fishing industry.

How were oral and injectable PrEP options evaluated in the trial?

Phase 1 randomized 400 HIV-negative men to oral or injectable PrEP for 9 months. Phase 2 was a choice phase where men selected which type of PrEP they wanted to use for 9 months.

What were the key results regarding persistence and preferences for CAB-LA versus oral PrEP?

Same-day HIV testing and CAB-LA initiation were highly acceptable and feasible for mobile men. CAB-LA users showed about 2.5× higher odds of persisting on PrEP than oral users, and at month 9, 58% chose CAB-LA versus 42% oral PrEP.

Sep 27, 2026

Uploaded by lilac